Answers are grounded in this paper and cite their sources.
Prospective study demonstrates improved fatigue and wellbeing in IBD, suggesting effective intervention.
Background Fatigue affects up to 70% of patients with inflammatory bowel disease (IBD), even in remission, and remains a major unmet need. Few active interventions specifically target this symptom. Solution-focused brief therapy (SFBT) is a short-term, goal- and resource-oriented psychotherapeutic approach that encourages autonomy, self-efficacy, and engagement. This study evaluated the impact of SFBT on fatigue, anxiety, depression, sleep quality, and wellbeing in IBD, and explored predictors of response and adherence. Methods Prospective, interventional, single-centre, uncontrolled study including adults with IBD and fatigue (Inflammatory Bowel Disease Fatigue score [IBD-F] > 1), stable IBD treatment for ≥3 months, and no corticosteroids. Fatigue (IBD-F1 and IBD-F2), anxiety and depression (Hospital Anxiety and Depression Scale [HADS]), sleep quality (Pittsburgh Sleep Quality Index [PSQI]) and wellbeing (Subjective Happiness Scale [SHS]) were assessed before and after SFBT. Therapy was delivered by a single trained therapist in 3–6 sessions, depending on individual progression. Adherence was considered complete when all sessions were attended and null when discontinued after the first. Results Sixty-seven patients were screened; six were referred for psychiatric management and eleven discontinued early. Fifty were analysed (68% female; median age 43 years; 65% Crohn’s disease). IBD-F1 correlated with SHS (r = 0.52, p < 0.0001), PSQI (r = 0.37, p = 0.0029), and HADS (r = 0.65, p < 0.0001). SFBT significantly improved IBD-F1 (p < 0.0001), IBD-F2 (p < 0.0001), HADS (p < 0.0001), PSQI (p = 0.0001), and SHS (p < 0.0001). Fatigue reduction was associated with female sex (p = 0.017), Montreal E1 vs E3 (p = 0.009), higher baseline IBD-F1 (p = 0.025) and lower body weight (p = 0.010). Reduced fatigue impact was linked to higher HADS (p = 0.012), perianal disease (p = 0.032) and absence of remission (p = 0.001). Complete adherence (71.6%) was associated with psychiatric follow-up (p = 0.001), antidepressant use (p = 0.006), shorter disease duration (p = 0.023), absence of follow-up during the COVID period (p = 0.035), and higher baseline fatigue (p = 0.017). Conclusion SFBT significantly improved fatigue, anxiety, depression, sleep, and quality of life in IBD, including in patients not in remission. These findings suggest that SFBT may represent a valuable integrative approach for IBD-related fatigue. Controlled multicentre trials are warranted to confirm efficacy and define optimal patient selection. Conflict of interest: Collin, Julie: No conflict of interest Moor, Laurent: Grant: Ferring, Janssen, Takeda, Fresenius, Biogen Personal Fees: Ferring, Janssen, Takeda, Fresenius, Abbvie, Galapagos, Pfizer, Celltrion, Thermofisher, BMS, Lilly, Thermofisher Monin, Lucie: No conflict of interest Latour, Pascale: No conflict of interest Van Kemseke, Catherine: No conflicts Vieujean, Sophie: No conflict of interest Louis, Edouard: Education and Reserach Grants for my department: Abbvie, Takeda, Johnson and Johnson, Pfizer, Fresenius-Kabi, Celltrion, EG pharma, Sandoz, Falk Personal Fees for conferences, advisory boards and consultancy: Abbvie, Takeda, Ferring, Pfizer, Johnson and Johnson, Lilly, Galapagos, Celltrion, Arena, BMS, Falk, Biokuris, Fresenius-Kabi, Thabor Prof. Dr. Reenaers, Catherine: This work supported by a grant from Takeda
No takes yet. Share an insight, caveat, or question.
Collin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: